As filed with the Securities and Exchange Commission on February 26, 2021

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

Form S-8

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

 

 

 

Tabula Rasa HealthCare, Inc.

(Exact Name of Registrant as Specified in its Charter)

  

 

 

Delaware   46-5726437

(State or other jurisdiction of
incorporation or organization)

 

(I.R.S. Employer
Identification Number) 

 

228 Strawbridge Drive, Suite 100

Moorestown, NJ 08057

(866) 648 - 2767 

(Address, including zip code, and telephone number, including area code, of Registrant’s principal executive offices)

 

 

Tabula Rasa HealthCare, Inc. 2016 Omnibus Incentive Compensation Plan

(Full title of the plan)

 

 

Dr. Calvin H. Knowlton, Ph.D.
Chief Executive Officer
Tabula Rasa HealthCare, Inc.
228 Strawbridge Drive, Suite 100
Moorestown, NJ 08057
(866) 648 - 2767

(Name, address, including zip code, and telephone number, including area code, of agent for service)

 

With copies to:

 

Kevin S. Shmelzer, Esq.

Morgan, Lewis & Bockius LLP

1701 Market Street

Philadelphia, PA 19103

(215) 963-5000

 

 

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

             
Large accelerated filer   x   Accelerated filer   ¨
       
Non-accelerated filer   ¨   Smaller reporting company   ¨
             
        Emerging growth company   ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨

 

 

CALCULATION OF REGISTRATION FEE

 

 

 

Title of securities
to be registered(1) 

 

Amount
to be
registered (2)
 

  

Proposed
maximum
offering price
per share (3)
 

  

Proposed
maximum
aggregate
offering price (3)
 

  

Amount of
registration fee
 

 
                     
Common Stock, par value $0.0001 per share   1,200,244   $47.78   $57,347,658.32   $6,256.63 

 

 

(1) This Registration Statement covers shares of the registrant’s common stock, par value $0.0001 per share (“Common Stock”), which are issuable pursuant to the Tabula Rasa HealthCare, Inc. 2016 Omnibus Incentive Compensation Plan (the “2016 Equity Compensation Plan”).
(2) Pursuant to Rule 416 under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement shall also cover any additional shares of the registrant’s Common Stock which become issuable under the 2016 Equity Compensation Plan by reason of any stock dividend, stock split, recapitalization, or any other similar transaction effected without the receipt of consideration which results in an increase in the number of outstanding shares of Common Stock.
(3) Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(h) and Rule 457(c) promulgated under the Securities Act. The offering price per share and the aggregate offering price are calculated based upon the average of the high and low prices of the registrant’s Common Stock as reported on The Nasdaq Global Market on February 22, 2021.

 

 

 

 

 

 

PART II

 

INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

 

EXPLANATORY NOTE 

 

This Registration Statement on Form S-8, relating to the Tabula Rasa HealthCare, Inc. 2016 Omnibus Incentive Compensation Plan (the “Plan”), is being filed pursuant to General Instruction E to Form S-8, for the purpose of registering an additional 1,200,244 shares (the “Shares”) of the common stock, par value $0.0001 per share, of Tabula Rasa HealthCare, Inc. (the “Registrant”). The Shares are securities of the same class and relate to the same employee benefit plan for which Registration Statements on Form S-8 have previously been filed and are effective. Accordingly, this Registration Statement incorporates by reference the contents of the Registration Statements on Form S-8, File Nos. 333-214025, 333-216674, 333-223658, 333-230046, and 333-236821 filed with the Securities and Exchange Commission on October 7, 2016, March 14, 2017, March 14, 2018, March 4, 2019 and March 2, 2020, respectively, by the Registrant, relating to the Plan, and the information required by Part II is omitted, except as supplemented by the information set forth below.

 

Item 8. Exhibits.

 

The following exhibits are filed as part of this Registration Statement:

 

     

Exhibit No. 

 

Exhibit 

   
4.1   Amended and Restated Certificate of Incorporation of Tabula Rasa HealthCare, Inc. (previously filed as Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed on October 4, 2016 and incorporated by reference herein)
   
4.2   Amended and Restated Bylaws of Tabula Rasa HealthCare, Inc. effective as of October 4, 2016 (previously filed as Exhibit 3.2 to the Registrant’s Current Report on Form 8-K filed on October 4, 2016 and incorporated by reference herein)
   
5.1   Opinion of Morgan, Lewis & Bockius LLP as to the legality of the securities being registered
   
23.1   Consent of Morgan, Lewis & Bockius LLP (included in the opinion filed as Exhibit 5.1)
   
23.2   Consent of KPMG LLP, independent registered public accounting firm, as to Tabula Rasa HealthCare, Inc.
   
24.1   Powers of Attorney (included on the signature page of this Registration Statement)
   
99.1   Tabula Rasa HealthCare, Inc. 2016 Omnibus Incentive Compensation Plan (previously filed as Exhibit 10.15 to the Registrant’s Amendment No. 3 to the Registration Statement on Form S-1 (File No. 333-208857) filed on September 19, 2016 and incorporated by reference herein)

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of City of Moorestown, State of New Jersey, on this 26th day of February, 2021.

 

  TABULA RASA HEALTHCARE, INC.
     
  By /s/ DR. CALVIN H. KNOWLTON
    Dr. Calvin H. Knowlton
    Chairman of the Board of Directors and
Chief Executive Officer

 

POWER OF ATTORNEY

 

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Dr. Calvin H. Knowlton and Brian W. Adams, and each one of them, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place, and stead, in any and all capacities, to sign any and all amendments to the Registration Statement on Form S-8 of Tabula Rasa HealthCare, Inc., and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, or his, her or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

 

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities indicated on this 26th day of February, 2021.

 

Signature   Title
     
/s/ DR. CALVIN H. KNOWLTON   Chairman of the Board of Directors and Chief Executive Officer
Dr. Calvin H. Knowlton   (principal executive officer)
     
/s/ BRIAN W. ADAMS   Chief Financial Officer
Brian W. Adams   (principal financial officer)
     
/s/ ANDREA SPEERS   Chief Accounting Officer
Andrea Speers   (principal accounting officer)
     
/s/ SAMIRA K. BECKWITH   Director
Samira K. Beckwith    
     
/s/ JAN BERGER   Director
Jan Berger    
     
/s/ DENNIS K. HELLING   Director
Dennis K. Helling    
     
/s/ ORSULA V. KNOWLTON   Director
Orsula V. Knowlton    
     
/s/ Kathrine O’ Brien   Director
Kathrine O’Brien    
     
/s/ MICHAEL PURCELL   Director
Michael Purcell    
     
/s/ PAMELA SCHWEITZER   Director
Pamela Schweitzer    
     
/s/ A GORDON TUNSTALL   Director
A Gordon Tunstall    

 

 

Exhibit 5.1

 

 

 

February 26, 2021

 

Tabula Rasa HealthCare, Inc.
228 Strawbridge Drive, Suite 100
Moorestown, NJ 08057

 

Re:Tabula Rasa HealthCare, Inc. Registration Statement on Form S-8 Filed on February 26, 2021

 

Ladies and Gentlemen:

 

We have acted as counsel to Tabula Rasa HealthCare, Inc., a Delaware corporation (the “Company”), in connection with its filing of a Registration Statement on Form S-8 (the “Registration Statement”) under the Securities Act of 1933, as amended (the “Act”), with the Securities and Exchange Commission (the “SEC”) on the date hereof. The Registration Statement relates to the offer and sale of 1,200,244 shares of common stock, par value $0.0001 per share, of the Company (the “Shares”), which may be issued under the Company’s 2016 Omnibus Incentive Compensation Plan (the “Plan”).

 

In connection with this opinion letter, we have examined the Registration Statement and originals, or copies certified or otherwise identified to our satisfaction, of (i) the Amended and Restated Certificate of Incorporation of the Company, as amended to date, (ii) the Amended and Restated Bylaws of the Company, as amended to date, (iii) certain resolutions of the Company’s Board of Directors relating to the Registration Statement, (iv) the Plan, and (v) such other documents, records and other instruments as we have deemed appropriate for purposes of the opinions set forth herein.

 

We have assumed the genuineness of all signatures, the legal capacity of all natural persons, the authenticity of the documents submitted to us as originals, the conformity with the originals of all documents submitted to us as certified, facsimile, or photostatic copies, and the authenticity of the originals of all documents submitted to us as copies. With respect to matters of fact relevant to our opinions as set forth below, we have relied upon certificates of officers of the Company, representations made by the Company in documents examined by us, and representations of officers of the Company. 

 

Subject to the foregoing and the other matters set forth herein, we are of the opinion, as of the date hereof that the Shares have been duly authorized by the Company and, when issued by the Company in accordance with the provisions of the Plan, will be validly issued, fully paid, and non-assessable.

 

The opinions expressed herein are limited to the Federal laws of the United States and the Delaware General Corporation Law.

 

We hereby consent to the use of this opinion as Exhibit 5.1 to the Registration Statement. In giving such consent, we do not hereby admit that we are acting within the category of persons whose consent is required under Section 7 of the Act or the rules or regulations of the Commission thereunder.

 

Very truly yours,

 

/s/ Morgan, Lewis & Bockius LLP

 

  Morgan, Lewis & Bockius llp
   
  1701 Market Street
  Philadelphia, PA 19103-2921 (T).png +1.215.963.5000
  United States (F).png +1.215.963.5001

 

 

 

Exhibit 23.2

 

Consent of Independent Registered Public Accounting Firm

 

The Board of Directors
Tabula Rasa HealthCare, Inc.:

 

We consent to the use of our reports dated February 26, 2021, with respect to the consolidated balance sheets of Tabula Rasa HealthCare, Inc. as of December 31, 2020 and 2019, the related consolidated statements of operations, stockholders’ equity, and cash flows for each of the years in the three-year period ended December 31, 2020, and the related notes and financial statement schedule II – valuation and qualifying accounts (collectively, the consolidated financial statements), and the effectiveness of internal control over financial reporting as of December 31, 2020, incorporated herein by reference.

 

Our report on the consolidated financial statements refers to a change in the accounting for leases as of January 1, 2019 due to the adoption of Accounting Standards Update (ASU) No. 2016-02, Leases (Topic 842) and ASU No. 2018-11, Leases (Topic 842): Targeted Improvements.

 

Our report dated February 26, 2021, on the effectiveness of internal control over financial reporting as of December 31, 2020, contains an explanatory paragraph that states that the Company acquired Personica, LLC during 2020, and management excluded from its assessment of the effectiveness of the Company’s internal control over financial reporting as of December 31, 2020, Personica, LLC’s internal control over financial reporting associated with approximately 14% of total assets and approximately 1% of total revenue included in the consolidated financial statements of the Company as of and for the year ended December 31, 2020. Our audit of internal control over financial reporting of the Company also excluded an evaluation of the internal control over financial reporting of Personica, LLC.

 

 

/s/ KPMG LLP

 

Philadelphia, Pennsylvania
February 26, 2021